ANTI-NAUSEANT 50 MG
DIMENHYDRINATE : 50 MG · DIN 02241532 · VITA HEALTH PRODUCTS INC
Health Canada status: MARKETED
What is ANTI-NAUSEANT?
ANTI-NAUSEANT 50 MG contains DIMENHYDRINATE : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02241532, held by VITA HEALTH PRODUCTS INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 01-May-2010. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What else is ANTI-NAUSEANT called?
The same molecule, DIMENHYDRINATE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| DIZINIL | Latin | Bahrain |
| DRAMAMINE | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02241532 |
|---|---|
| Brand name | ANTI-NAUSEANT |
| Generic / active ingredient | DIMENHYDRINATE : 50 MG |
| Manufacturer | VITA HEALTH PRODUCTS INC |
| Strength | 50 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | R06AA11 DIMENHYDRINATE |
| AHFS class | 56:22.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 01-May-2010 |
| Original market date | 2000-05-01 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02241532 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2241532 |
| Brand name | ANTI-NAUSEANT |
| Active ingredient / INN | DIMENHYDRINATE : 50 MG |
| ATC code | R06AA11 |
| ATC anatomical main group | R — Respiratory system |
| ATC therapeutic subgroup | R06 |
| AHFS class | 56:22.08 |
| Health Canada schedule | NON-PRESCRIPTION DRUGS |
| Biosimilar biologic | No |
| Market authorization holder | VITA HEALTH PRODUCTS INC |
Which pack is which?
| Strength on the label | 50 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Is DIMENHYDRINATE in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code R06AA11 DIMENHYDRINATE. 20 of 70 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ANTI-NAUSEANT LIQUID GELS | 50 MG | CAPSULE | VITA HEALTH PRODUCTS INC | MARKETED | DIN 02493004 |
| CONFAB DIMENHYDRINATE 100 MG | 100 MG | SUPPOSITORY | LABORATOIRES CONFAB INC | MARKETED | DIN 00392545 |
| CONFAB DIMENHYDRINATE 50 MG | 50 MG | SUPPOSITORY | LABORATOIRES CONFAB INC | MARKETED | DIN 00392553 |
| DIMENHYDRINATE INJECTION USP | 10 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 00392731 |
| DIMENHYDRINATE INJECTION USP | 250 MG / 5 ML | SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02435241 |
| DIMENHYDRINATE INJECTION USP | 50 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 00392537 |
| DIMENHYDRINATE INJECTION USP | 50 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02536536 |
| DIMENHYDRINATE INJECTION USP | 50 MG / 1 ML | SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02428954 |
| GAVISCON NAUSEA | 50 MG | TABLET | MEDTECH PRODUCTS INC | MARKETED | DIN 02490528 |
| GRAVOL CHEWABLES | 50 MG | TABLET (CHEWABLE) | CHURCH & DWIGHT CANADA CORP | MARKETED | DIN 02384132 |
Who else supplies DIMENHYDRINATE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DIMENHYDRINATE appears in 8 registered pack listings across 5 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does DIMENHYDRINATE cost around the world?
DIMENHYDRINATE is listed on 5 national price registers Nexara tracks, across 7 pack listings published on 4 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United Arab Emirates | public | 1 | 2 | 31 Aug 2026 |
| Saudi Arabia | public | 2 | 2 | 01 Sep 2026 |
| Bahrain | retail (max) | 1 | 1 | 01 Sep 2026 |
| Greece | producer price (ex-factory) | 1 | 1 | 03 Sep 2026 |
| Morocco | PPV (public price) | 1 | 1 | 05 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.